Drug intelligence / Profile preview

GSKVX000000044501

Development stage
Phase 2
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**GSKVX000000044501** is an investigational GSK prophylactic vaccine active substance being evaluated as part of a urinary tract infection vaccine program. It is being studied for prevention of new *Escherichia coli*-associated urinary tract infections, with safety, reactogenicity, immunogenicity, and clinical efficacy assessed in adults and in females aged 18 to 64 years. Public trial information identifies it as a vaccine-related active substance administered in an intramuscular suspension-for-injection product; its precise antigen composition, vaccine platform, and adjuvant system have not been publicly disclosed.

Other names
9-valent extraintestinal pathogenic Escherichia coli bioconjugate vaccineExPEC-9VExPEC9VExPEC 9V
02

Targets

EPA (Pseudomonas aeruginosa exotoxin A)O1a (Escherichia coli O1a antigen)O2 antigen (Escherichia coli O2 antigen)O25b (Escherichia coli O25b antigen)

Beyond the preview

Go deeper on GSKVX000000044501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSKVX000000044501.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call